Fri Aug 14 2020
suPARnostic® TurbiLatex will now be available for clinical decision making in the Emergency Department of Hospital Clínico Universitario Virgen de la Arrixaca, located in the Murcia region in Spain.
The hospital has started to use suPARnostic® TurbiLatex on its Roche cobas platform to help the process of triage in the emergency department, with a focus on triage in relation to COVID-19 disease.
This is the second hospital in the Murcia region and the third Spanish hospital this year, that has adopted the suPARnostic® TurbiLatex product in clinical routine use.
In June, the Hospital General Universitario Santa Lucía in Cartagena, also in the Murcia region, started measuring suPAR on its Roche cobas platform, to help the process of triage in the emergency department.
In April, the León Hospital in the Castilla y León region in Spain implemented suPARnostic® in clinical routine.
The Arrixaca University Hospital is the biggest hospital in the Murcia region with around 1200 beds and an uptake population of around 1.4 million people.
As the Murcia region, like the rest of Spain is very affected by COVID-19 disease, the hospital is handling around 60 patients per day with COVID-19 disease and with a surge in the trend. The implementation has been led by Dr. Jose Antonio Noguera Velasco, head of the laboratory and his team.
Dr. Noguera says in a comment:
“Given the previous studies, we have high expectations that the measurement of suPAR will help us in stratification, and therefore in improving the care of our patients, especially in the current circumstances in which the CoVID-19 pandemic seriously compromises our healthcare system.”
Jakob Knudsen, CEO of ViroGates, says:
”We are excited to work with the biggest hospital in the Murcia region and happy that the doctors at the hospital appreciated the data created at other hospitals in Spain –particularly the hospital in Cartagena being part of the same region. We are convinced that the implementation will be of high value in the triage of patients both in this very challenging Corona virus setting and beyond.”